A Study of HS269 in Patients With Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
This is a Phase I, open-label, first in human study of HS269 tablet, a small molecule highly-selective RET Inhibitor. The dose-escalation study will assess the safety, tolerability, and pharmacokinetics of HS269 and determine the dose and schedule to be used in Phase II. Seventeen to thirty-six patients with advanced solid tumor may be enrolled in this study.

Official Title
-----------------
A Phase I, Open-label，Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS269, in Patients With Advanced Solid Tumor

Conditions
-----------------
Advanced Solid Tumor

Intervention / Treatment
-----------------
* Drug: HS269


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18 years, no gender limit. Patients with advanced solid tumors confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment, or standard treatment is not applicable at this stage. At least one evaluable tumor lesion according to RECIST version 1.1. ECOG≤ 1. The estimated survival time was more than 3 months. The function of all organs was good, the specific indexes were as follows: Blood system (no transfusion or hematopoietic stimulating factor treatment within 14 days) i. #NEUT ≥1.5×109/L ii. PLT ≥90×109/L iii. HGB ≥85g/L Liver function i. TBIL ≤1.5×ULN ii. ALT ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN iii. AST ≤3×ULN; Patients with liver metastasis or liver cancer: ≤ 5 × ULN Renal function i. Ccr >50 ml/min（According to Cockcroft-Gault formula） Blood coagulation function i. APTT ≤1.5×ULN ii. INR ≤1.5×ULN The subjects should be informed and agreed to the study before the start of the trial, and sign the written informed consent voluntarily. Exclusion Criteria: Received anti-tumor treatments within 14 days or less than 5 half-lives (whichever is longer) before the first use of the study drug Received blood transfusion, erythropoietin, recombinant human thrombopoietin or colony stimulating factor and other treatments within 7 days before receiving blood system examination during the screening period. Received other unmarketed clinical study drugs or treatments within 4 weeks before the first use of the study drug. Major organ surgery (excluding biopsy) or significant trauma occurred within 4 weeks before the first use of the study drug; Systemic administration of glucocorticoids (prednisone > 10 mg / day or equivalent dose of the same drug) or other immunosuppressants within 14 days before the first use of the study drug; except for local, eye, intra articular, nasal and inhaled corticosteroids; short-term use of glucocorticoids for preventive treatment (e.g. prevention of contrast agent allergy)； CYP1A2/P-gp potent inhibitors or potent inducers were used within 7 days before the first use of the study drug； Resistance to selective RET inhibitors; The adverse reactions of previous anti-tumor therapy have not yet recovered to CTCAE 5.0 grade evaluation ≤ 1 (except for the toxicity without safety risk judged by researchers such as alopecia)； Patients with central nervous system metastasis or meningeal metastasis with clinical symptoms, or other evidence indicating that the central nervous system metastasis or meningeal metastasis has not been controlled, which is not suitable for the study. Have active infection and need systemic anti infection therapy； Have a history of immunodeficiency, including HIV antibody test positive； Active hepatitis B, allowing preventive antiviral treatment other than interferon; hepatitis C virus infection； Present or past interstitial lung disease (except radiation-induced pulmonary fibrosis without hormone therapy)； Poorly controlled diabetic patients. Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: Serious abnormal cardiac rhythm or conduction, such as ventricular arrhythmia, Ⅱ - Ⅲ degree atrioventricular block, etc; In the resting state, average QTcF≥480ms in 12 lead -ECG； Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular events of grade 3 or above occurred within 6 months before the first administration; NYHA ≥II or LVEF<50％； Hypertension beyond clinical control； Could not take medication orally，or have severe gastrointestinal obstruction (such as gastrointestinal obstruction, gastrointestinal absorption)； The third space effusion, which could not be controlled clinically, was not suitable for the study； Mental disorder or poor compliance； Eligible patients with fertility (male and female) do not agree to use reliable contraceptive methods (abstinence, condom, intrauterine device or ligation) with their partner during the trial and for at least 3 months after the last medication. Female patients have a positive blood pregnancy test within 7 days before enrollment, or breastfeeding women; The subjects were not suitable for the clinical study because of other serious systemic diseases or other reasons according to the investigator 's judgment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HS269<br>Multiple doses of HS269 tablets | Drug: HS269<br>* Oral tablets, once daily. Dose escalation from 50 mg QD, through 100 mg, 200mg, 300 mg, 400 mg, to 500mg.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose limiting toxicities (DLT) | Incidence rate of dose limiting toxicities (DLT) | From date of initial dose until up to 33 days for treatment | 
| Adverse Event(s) and Serious Adverse Event(s) | The occurrence and rate of AE and SAE | Through study completion or early study discontinuation（up to 12 months） | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak Plasma Concentration (Cmax) | Cmax of HS269 | From date of initial dose until up to 33 days for treatment | 
| Area Under the Plasma Concentration versus Time Curve (AUC) | AUC of HS269 | From date of initial dose until up to 33 days for treatment | 
| Calcitonin in Peripheral Blood | For Medullary Thyroid Cancer patients | Through study completion or early study discontinuation（up to 12 months） | 
| Thyroglobulin in Peripheral Blood | For non-MTC thyroid cancer patients | Through study completion or early study discontinuation（up to 12 months） | 
| ORR | Objective response rate (ORR) | Approximately 12 months | 
| DCR | Disease control rate (DCR) | Approximately 12 months | 
| PFS | Progression free survival (PFS) | Approximately 12 months | 
| Peripheral blood ctDNA | Only for patients with positive RET gene mutation | Through study completion or early study discontinuation（up to 12 months） |